Inflammatory breast carcinoma
MONDO:0006804An advanced, invasive breast adenocarcinoma characterized by the presence of distinct changes in the overlying skin. These changes include diffuse erythema, edema, peau d'orange (skin of an orange) appearance, tenderness, induration, warmth, enlargement, and in some cases a palpable mass. The skin changes are the consequence of lymphatic obstruction from the underlying invasive breast adenocarcinoma. Microscopically, the dermal lymphatics show prominent infiltration by malignant cells. The invasive breast adenocarcinoma is usually of ductal, NOS type. There is not significant inflammatory cell infiltrate present, despite the name of this carcinoma.
Also known as: inflammatory breast cancer, inflammatory breast carcinoma, inflammatory carcinoma of breast, inflammatory carcinoma of the breast, mastitis Carcinomatosa, mastitis carcinomatosa, IBC, breast cancer, inflammatory
2827 clinical trials for this condition and its sub-types, 29 tagged with Inflammatory breast carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug combo takes on deadly breast cancer in small trial
Disease control CompletedThis study tests whether adding the drug ruxolitinib to standard chemotherapy can help treat triple-negative inflammatory breast cancer, a rare and aggressive form of breast cancer. About 23 adults with this diagnosis will receive the combination before surgery. The goal is to se…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Triple threat: new combo shows promise against tough breast cancer
Disease control CompletedThis phase II trial tested a combination of two targeted antibodies (pertuzumab and trastuzumab) plus a chemotherapy drug (nab-paclitaxel) in 63 patients with HER2-positive advanced breast cancer. The goal was to see how well the drugs work together to stop tumor growth and impro…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
High-Dose chemo combo shows promise for tough breast cancers
Disease control CompletedThis study tested whether giving higher doses of two chemotherapy drugs (epirubicin and docetaxel) along with a drug to boost immune recovery (pegfilgrastim) could help women with advanced or inflammatory breast cancer. 93 women took part. The goal was to see how well the treatme…
Phase 1/2 • Sponsor: NCIC Clinical Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Aggressive chemo combo with stem cell rescue tested for rare breast cancer
Disease control CompletedThis phase II trial tested a very strong chemotherapy regimen followed by a stem cell transplant in 41 people with stage IIIB inflammatory breast cancer. The goal was to see if this intense approach could help keep the cancer from coming back and improve survival. Participants re…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug cocktail shows promise against aggressive breast cancer
Disease control CompletedThis study tested a combination of chemotherapy (paclitaxel) and two targeted antibodies (trastuzumab and pertuzumab) given before mastectomy to 23 women with HER2-positive inflammatory breast cancer. The goal was to see if the treatment could wipe out all cancer in the breast an…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Home sweet home? breast cancer patients may prefer At-Home drug infusions
Symptom relief CompletedThis study looked at whether people with early or locally advanced HER2-positive breast cancer prefer receiving their medication (a combination of pertuzumab and trastuzumab) at home versus in the hospital. About 346 participants were randomly assigned to receive the drug at home…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC